Switch theme
Sign up to access all valuation multiples
Sysmex Corp manufactures and distributes in vitro diagnostic instruments, reagents, and software. The vast majority of the firm's revenue comes from selling tests for human bodily fluids to hospitals and commercial laboratories. Within this industry, the firm specializes in hematology reagents and instruments. Sysmex also sells in vitro diagnostics for applications like urinalysis and hemostasis and provides support and maintenance services for its systems. Over half of the firm's revenue is generated by sales of reagents and services, which are recurring sources of income. Sysmex primarily sells its products to customers in Japan, Europe, the Middle East, and Africa, and the Americas.
1968
8.6K+
LTM Revenue $3.5B
LTM EBITDA $888M
$10.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sysmex has a last 12-month revenue (LTM) of $3.5B and a last 12-month EBITDA of $888M.
In the most recent fiscal year, Sysmex achieved revenue of $3.2B and an EBITDA of $775M.
Sysmex expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sysmex valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.5B | XXX | $3.2B | XXX | XXX | XXX |
| Gross Profit | $1.9B | XXX | $1.7B | XXX | XXX | XXX |
| Gross Margin | 53% | XXX | 53% | XXX | XXX | XXX |
| EBITDA | $888M | XXX | $775M | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 24% | XXX | XXX | XXX |
| EBIT | $612M | XXX | $553M | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $378M | XXX | $341M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 11% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Sysmex's stock price is JPY 2432 (or $17).
Sysmex has current market cap of JPY 1.52T (or $10.4B), and EV of JPY 1.49T (or $10.2B).
See Sysmex trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10.2B | $10.4B | XXX | XXX | XXX | XXX | $0.61 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Sysmex has market cap of $10.4B and EV of $10.2B.
Sysmex's trades at 3.3x EV/Revenue multiple, and 13.5x EV/EBITDA.
Equity research analysts estimate Sysmex's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sysmex has a P/E ratio of 27.5x.
See valuation multiples for Sysmex and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $10.4B | XXX | $10.4B | XXX | XXX | XXX |
| EV (current) | $10.2B | XXX | $10.2B | XXX | XXX | XXX |
| EV/Revenue | 2.9x | XXX | 3.3x | XXX | XXX | XXX |
| EV/EBITDA | 11.5x | XXX | 13.5x | XXX | XXX | XXX |
| EV/EBIT | 16.7x | XXX | 18.8x | XXX | XXX | XXX |
| EV/Gross Profit | 5.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 27.5x | XXX | 31.2x | XXX | XXX | XXX |
| EV/FCF | 38.6x | XXX | 88.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSysmex's last 12 month revenue growth is 6%
Sysmex's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Sysmex's rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sysmex's rule of X is 41% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sysmex and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | 16% | XXX | XXX | XXX |
| Rule of 40 | 31% | XXX | 31% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 41% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 35% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sysmex acquired XXX companies to date.
Last acquisition by Sysmex was XXXXXXXX, XXXXX XXXXX XXXXXX . Sysmex acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sysmex founded? | Sysmex was founded in 1968. |
| Where is Sysmex headquartered? | Sysmex is headquartered in Japan. |
| How many employees does Sysmex have? | As of today, Sysmex has 8.6K+ employees. |
| Who is the CEO of Sysmex? | Sysmex's CEO is Mr. Hisashi Ietsugu. |
| Is Sysmex publicy listed? | Yes, Sysmex is a public company listed on TKS. |
| What is the stock symbol of Sysmex? | Sysmex trades under 6869 ticker. |
| When did Sysmex go public? | Sysmex went public in 1996. |
| Who are competitors of Sysmex? | Similar companies to Sysmex include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Sysmex? | Sysmex's current market cap is $10.4B |
| What is the current revenue of Sysmex? | Sysmex's last 12 months revenue is $3.5B. |
| What is the current revenue growth of Sysmex? | Sysmex revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Sysmex? | Current revenue multiple of Sysmex is 2.9x. |
| Is Sysmex profitable? | Yes, Sysmex is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sysmex? | Sysmex's last 12 months EBITDA is $888M. |
| What is Sysmex's EBITDA margin? | Sysmex's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Sysmex? | Current EBITDA multiple of Sysmex is 11.5x. |
| What is the current FCF of Sysmex? | Sysmex's last 12 months FCF is $265M. |
| What is Sysmex's FCF margin? | Sysmex's last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of Sysmex? | Current FCF multiple of Sysmex is 38.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
